Roy Wiesner

At Eleos, we believe the path to better care is paved with provider-focused technology. Our purpose-built AI platform streamlines documentation, simplifies compliance, and surfaces deep care insights to drive better client outcomes. Created using the industry’s largest database of real-world behavioral health sessions and fine-tuned by our in-house clinical experts, our AI tools are scientifically proven to reduce documentation time by more than 70%, boost client engagement by 2x, and improve symptom reduction by 3–4x. With Eleos, behavioral health providers are free to focus less on administrative tasks and more on what got them into this field in the first place: caring for their clients.

Ibex Medical Analytics pioneers AI-based cancer diagnostics in pathology. Pathologists are challenged to provide accurate and timely cancer diagnoses as their workloads keep increasing due to a rise in cancer prevalence and advances in personalized medicine that result in growing diagnostic complexity. We use artificial intelligence (AI) to develop clinical-grade algorithms and digital workflows that detect cancer as accurately as a human pathologist. Our platform demonstrated outstanding outcomes in clinical studies and helps pathologists and providers eliminate diagnostic errors, implement real-time quality control, reduce diagnosis time and boost productivity. Deployed worldwide, Ibex is the first-ever AI-powered cancer diagnostics platform used in routine clinical practice in pathology labs, with demonstrated success in improving the quality and efficiency of cancer diagnosis. We are a multidisciplinary team of entrepreneurs, data scientists, software engineers and medical experts, working together to realize our vision: transform cancer diagnosis with AI and improve patient care. If you are an outstanding professional constantly looking for challenges, passionate about your work, a team player and want to make real impact – we want to hear from you.

At AtaCor Medical, we envision a new world of cardiac rhythm management. As a result, we are designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. Representing the future of temporary pacing without the risks, costs, and drawbacks of traditional methods, the AtaCor EV Temporary Pacing Lead System is designed to: - Enable reliable, prompt, imaging-free temporary pacing with safe post-procedure ambulation - Eliminate the complications associated with transvenous leads - Eliminate the patient discomfort of transcutaneous pacing The AtaCor EV Temporary Pacing System is under development and not approved for sale in any geography.

At AtaCor Medical, we envision a new world of cardiac rhythm management. As a result, we are designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. Representing the future of temporary pacing without the risks, costs, and drawbacks of traditional methods, the AtaCor EV Temporary Pacing Lead System is designed to: - Enable reliable, prompt, imaging-free temporary pacing with safe post-procedure ambulation - Eliminate the complications associated with transvenous leads - Eliminate the patient discomfort of transcutaneous pacing The AtaCor EV Temporary Pacing System is under development and not approved for sale in any geography.

Igentify® is a digital health company. We help clinicians, laboratories, and patients access, interpret, and use genetic information and education more effectively. Igentify developed the world’s first Digital Genetic Assistant, a software-based decision support platform. Our platform is capable of providing a fully scalable end-to-end genetic counseling solution in both clinical as well as non-clinical (direct-to-consumer) genetic testing set up. The platform is built for various genotyping technologies like microarray and next-generation sequencing (NGS). It can be customized to a broad spectrum of genetic and genomic tests offered by the test providers. Founded in Oct. 2016, Igentify’s team of globally renowned geneticists, highly experienced software developers, creative animators, and UX/UI designers, is redefining the protocols of traditional medicine. In Jan. 2019, Deloitte selected Igentify as one of the Israeli startups at the forefront of the Digital R&D Revolution.

TripleW upcycles food waste into high-value, high-demand lactic acid, utilizing a climate transformative technology.

HydroSpin is the leading provider for smart energy solutions for Smart Water. HydroSpin’s micro-generator creates enough power to support remote devices 24/7 throughout the water network such as sensors and transmission devices, powering online transmission. This available power source enables much more data harvesting from the network, improving sustainability and reliability of water networks. HydroSpin generate electricity from the flow of water inside pipeline (off grid). The electricity we produced can be used for various applications including- water monitoring systems, water quality, data logger, PRV, sensors, AMR etc.

Aquarius Spectrum provides acoustic solutions that enable water utilities to proactively monitor their distribution pipe network, solve infrastructure issues, detect background leaks, reduce NRW and operational costs and assess the pipes’ condition. These solutions combines sensitive sensors powered by sophisticated algorithms, big data analysis and advanced connectivity (CAT-M/NB-IoT). By using our most innovative water network monitoring platform that enables accurate pinpointing of leaks and identification of poor pipe sections for renewal - water utilities improve the resiliency of their new and aging water network infrastructure.

Magentiq Eye Ltd., ISO 13485:2016 certified company, was established in 2014 with the aim to harness the most cutting edge computer vision and deep learning techniques to aid doctors in endoscopic procedures. Doctors today spend hours during Endoscopic Procedures looking at the LCD screens in order to explore, examine and treat various conditions. At Magentiq Eye we put the growing power of Deep Learning, Image and Video Processing to the help of doctors, so they can be more accurate and effective - ultimately saving millions of lives and billions of dollars. Our first product is MAGENTIQ-COLO™, which is used to increase the polyp (Adenoma) detection rate and the quality of the colonoscopy and Upper GI examinations, is a real-time device adjunct to the colonoscopy/gastroscopy device. Our MAGENTIQ-COLO™ points out the suspicious locations of polyps in the colonoscopy video, increases the attentiveness of doctors during procedures, thus helps them to reduce their polyp miss-rates. Given the large population that annually undergoes colonoscopy, even a modest decrease in polyp miss-rate can save a lot of lives! The MAGENTIQ-COLO™ has a CE Mark and FDA clearance and the pivotal multicenter international clinical trial on it was finished with successful results and published at the Lancet Digital Health (https://www.thelancet.com/journals/landig/article/PIIS2589-7500(23)00242-X/fulltext). Its extended version includes additional features such as polyp size estimation, polyp characterization additional quality measurements calculations for Upper and Lower GI, and monitoring the progress of specific diseases such as IBD and Barretts.

At Eleos, we believe the path to better care is paved with provider-focused technology. Our purpose-built AI platform streamlines documentation, simplifies compliance, and surfaces deep care insights to drive better client outcomes. Created using the industry’s largest database of real-world behavioral health sessions and fine-tuned by our in-house clinical experts, our AI tools are scientifically proven to reduce documentation time by more than 70%, boost client engagement by 2x, and improve symptom reduction by 3–4x. With Eleos, behavioral health providers are free to focus less on administrative tasks and more on what got them into this field in the first place: caring for their clients.

Ibex Medical Analytics pioneers AI-based cancer diagnostics in pathology. Pathologists are challenged to provide accurate and timely cancer diagnoses as their workloads keep increasing due to a rise in cancer prevalence and advances in personalized medicine that result in growing diagnostic complexity. We use artificial intelligence (AI) to develop clinical-grade algorithms and digital workflows that detect cancer as accurately as a human pathologist. Our platform demonstrated outstanding outcomes in clinical studies and helps pathologists and providers eliminate diagnostic errors, implement real-time quality control, reduce diagnosis time and boost productivity. Deployed worldwide, Ibex is the first-ever AI-powered cancer diagnostics platform used in routine clinical practice in pathology labs, with demonstrated success in improving the quality and efficiency of cancer diagnosis. We are a multidisciplinary team of entrepreneurs, data scientists, software engineers and medical experts, working together to realize our vision: transform cancer diagnosis with AI and improve patient care. If you are an outstanding professional constantly looking for challenges, passionate about your work, a team player and want to make real impact – we want to hear from you.

At AtaCor Medical, we envision a new world of cardiac rhythm management. As a result, we are designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. Representing the future of temporary pacing without the risks, costs, and drawbacks of traditional methods, the AtaCor EV Temporary Pacing Lead System is designed to: - Enable reliable, prompt, imaging-free temporary pacing with safe post-procedure ambulation - Eliminate the complications associated with transvenous leads - Eliminate the patient discomfort of transcutaneous pacing The AtaCor EV Temporary Pacing System is under development and not approved for sale in any geography.

At AtaCor Medical, we envision a new world of cardiac rhythm management. As a result, we are designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. Representing the future of temporary pacing without the risks, costs, and drawbacks of traditional methods, the AtaCor EV Temporary Pacing Lead System is designed to: - Enable reliable, prompt, imaging-free temporary pacing with safe post-procedure ambulation - Eliminate the complications associated with transvenous leads - Eliminate the patient discomfort of transcutaneous pacing The AtaCor EV Temporary Pacing System is under development and not approved for sale in any geography.